Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 2,500
- 试验地点
- 8
- 主要终点
- Measurement of inflammatory cytokines (interleukin (IL) 1 beta, IL-1RA, IL-6, IL-18, tumor necrosis factor (TNF) alpha, CXCL9 and CXCL10) on serum of patients
研究概览
简要总结
A multi-centre, prospective study to study cytokine profiles and other potential disease-specific biomarkers in patients with presumed or confirmed diseases of systemic inflammation
The goal of this prospective, observational study is to describe the longitudinal evolution of blood cytokine profiles in patients with presumed or confirmed diseases of systemic inflammation
The main questions it aims to answer are:
- What are the differences and similarities in blood cytokines between different patients and groups presenting symptoms of systemic inflammatory conditions?
- How is the cytokine profile of individual patients evolving over time and what is the effect of different therapeutics?
- Is cytokine profiling a valuable tool to diagnose and follow-up on patients with systemic inflammatory conditions?
Participants will be asked to give an additional blood volume for research purposes when blood sampling is performed for routine clinical purposes. A subset of patients (those initiated on biologicals) will also be asked to complete questionnaires.
Researchers will compare the blood cytokines profiles between the different groups of systemic inflammatory conditions and with healthy individuals.
详细描述
FEBRIS is a prospective, observational and multi-centric study involving 5 hospitals in Flanders, Belgium.
In this study, the researchers will us ehe FEBRIS Cytokine Profile Assay, which is a multiplex assay measuring pro- and anti-inflammatory cytokines in the blood of subjects. It has been developed in a retrospective cohort of human patients presenting systemic inflammatory disorders.
With this study, the researchers aim to prospectively validate the use of this assay in a cohort of patients that present signs reminiscent of systemic inflammation, including patients with antoinflammatory conditions, autoimmune disorders, hyperinflammatory syndromes (e.g. hemophagocytic lymphohistiocytosis and macrophage activation syndrome) and systemic infection. In parallel, serum amyloid A will be quantified in all patients. Lipidomics will be performed on patients with sufficient leftover sample. The researchers will integrate the data from these assays with clinical parameters at baseline and during follow-up to correlate markers with the clinical or genetic diagnosis, prognosis and effect of different therapeutics.
Patients fulfilling the inclusion criteria are eligible for longitudinal blood sampling (every 3-6 months) during the study period (maximum of 4 years). Additional clotted blood will only be collected when a blood sample for routine clinical purposes is performed.
In addition, patients initiated on biological therapeutics will be asked to complete questionnaires regarding health-related quality of life to document outcome and improve rational and cost-efficient use of additional investigations and treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
盲法说明
Pseudonymisation of samples and clinical data for the investigator
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •An individual who meets any of the following criteria can be eligible for participation in this study:
- •Child or adult
- •Written informed consent
- •Suspected or confirmed disease with systemic inflammation (acute, chronic and/or recurrent), these include:
- •Autoinflammatory diseases (AID), including among others: systemic onset juvenile idiopathic arthritis (sJIA), familial mediterranean fever (FMF), mevalonate kinase deficiency (Hyper IgD syndrome), TNF receptor-associated periodic syndrome (TRAPS), familial Cold Autoinflammatory Syndrome (CAPS), type 1 interferonopathies,...
- •Autoimmune diseases (AI), including among others: systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), rheumatoid arthritis (RA),...
- •Hyperinflammatory diseases, including among others: hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), infection-related cytokine storm (e.g. in the setting of COVID-19)
- •Other unidentified or not yet identified systemic inflammatory conditions
- •Blood sample for diagnostic purposes is planned and possibility to acquire additional blood volume
排除标准
- •An individual who meets any of the following criteria will be excluded from participation in this study:
- •Confirmed localized infection and/or good response to first-line antibiotic treatment
- •Confirmed malignancy
- •Besides the above mentioned patients, volunteers that meet the requirements as a healthy individual are eligible for inclusion as controls.
结局指标
主要结局
Measurement of inflammatory cytokines (interleukin (IL) 1 beta, IL-1RA, IL-6, IL-18, tumor necrosis factor (TNF) alpha, CXCL9 and CXCL10) on serum of patients
时间窗: full study period (up to 48 months)
On the sera of patients, the FEBRIS Cytokine Profile Assay will be performed. The FEBRIS Cytokine Profile Assay is a multiplex panel of inflammatory cytokines (interleukin (IL) 1 beta, IL-1RA, IL-6, IL-18, tumor necrosis factor (TNF) alpha, CXCL9 and CXCL10) that will be assessed by Meso Scale Discovery (MSD) technology. The concentration of cytokines will be quantified in pg/ml. Sera will be analyzed upon entry in the study and during follow-up (minimum interval of 3 months between samples). Data analyses (multiple logistic regression) will be performed on the cytokine fingerprints of different patient groups taking clinical control of patients into account (sampling during a flare of inflammation versus sampling during disease remission).
次要结局
- Registration of biological sex(full study period (up to 48 months))
- Registration of length(full study period (up to 48 months))
- Registration of age(full study period (up to 48 months))
- Registration of weight(full study period (up to 48 months))
- Additional measurement of inflammatory cytokines ((interleukin (IL) 1 beta, IL-1RA, IL-6, IL-18, tumor necrosis factor (TNF) alpha, CXCL9 and CXCL10) on serum of patients that are initiated on biological treatment(full study period (up to 48 months))
- Registration of health-related quality of life(full study periode (up to 48 months))
- Registration of confirmed or presumed inflammatory diseases(full study period (up to 48 months))
- Registration of clinical symptoms related to inflammatory diseases(full study period (up to 48 months))
- Registration of health-related costs(full study periode (up to 48 months))
- Registration of current therapy(full study period (up to 48 months))